2105

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for cancer and liver diseases worldwide. Its products include LAE002, an adenosine triphosphate competitive AKT for the treatment of ovarian cancer, prostate cancer, breast cancer, and programmed death-1/programmed death ligand-1 (PD-L1) drug-resistant solid tumors; and LAE001, an androgen synthesis inhibitor that inhibits cytochrome P450 family 17 subfamily A member 1 and cytochrome P450 family 11 subfamily B member 2 to treat prostate cancer. The company also develops LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody; LAE003 for the treatment of hereditary hemorrhagic telangiectasia and proteus syndrome; LAE102, a potent and selective activin receptor type IIA monoclonal antibody for cancer treatment; and LAE105, an activated hepatic stellate cell depletion to treat liver fibrosis. In addition, its inhibitory receptors expressed by cancer infiltrating lymphocytes include LAE109, LAE111, LAE113, and LAE117; and ligands/receptors expressed on or produced by cancer cells comprise LAE112. Further, the company develops liver fibrosis drug candidates, such as LAE104 and LAE106; and cancer drug candidates, including LAE118, LAE119, and LAE120. Laekna, Inc. was incorporated in 2016 and is headquartered in Shanghai, China. Show More...